The biopharmaceutical company released full results from its Phase 3 clinical trial conducted in China in type 2 diabetic patients with BioChaperone Lispro during the 86th Scientific Sessions of the American Diabetes Association.
According to Olivier Soula, CEO and co-founder of Adocia: 'Our Chinese partner Tonghua Dongbao reached a major milestone in 2025: the Phase 3 trial involving over 1,000 people with type 2 diabetes confirms the excellent performance of BioChaperone Lispro. For the first time, a prandial insulin has demonstrated superior glycemic control in type 2 diabetic patients across all three daily meals compared to Humalog, one of the world's most widely used prandial insulins'.
Adocia highlighted significant clinical advantages over Humalog: improved long-term glycemic control in patients on metformin or with HbA1c levels below 8.5%, and superior blood glucose control throughout the day and after each meal for the overall population.
Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity. The Company has a broad portfolio of drug candidates based on four proprietary technology platforms : BioChaperone® for the stabilization and enhancement of peptide formulations and combinations, AdoXLongTM, a long-acting peptide platform, AdOral®, an oral peptide delivery technology, and AdoShell®, an immunoprotective biomaterial for cell transplantation, with an initial application in pancreatic cells transplantation.
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
-
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
-
Quality
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
-
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
